Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.48 |
| ▸ | NPY1R | P25929 | 9/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.48 |
| ▸ | NPY2R | P49146 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12285427 | 0.90 | GNPAT (0.52) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL2552629 | 0.90 | GNPAT (0.52) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL24040280 | 0.89 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL12099664 | 0.88 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL12285389 | 0.88 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL21464836 | 0.88 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL21464838 | 0.88 | NPY4R (0.49) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL24488479 | 0.86 | NPY4R (0.51) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL12285733 | 0.86 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RNPC1 | |
| SCHEMBL10168797 | 0.85 | NPY4R (0.67) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20160235694-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | 3I, LP | 2016-08-18 | — | — | US | disclosed |
| WO-2011133348-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | PHARMACOFORE, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11179355-B2 | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof | ACHE, COMT, CES2 | NPY4R 2732/4885NPY1R 2108/4885NPY5R 1714/4885 |
| US-20160235694-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | NPY4R 2732/4885NPY1R 2108/4885NPY5R 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.